DICE Therapeutics, Inc.
DICE · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.21 | 1.07 | 2.77 | 1.11 |
| FCF Yield | -1.38% | -1.67% | -1.29% | -2.08% |
| EV / EBITDA | -62.62 | -49.26 | -50.87 | -36.50 |
| Quality | ||||
| ROIC | -7.43% | -4.34% | -4.44% | -7.47% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.87 | 0.77 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -34.31% | -23.51% | -15.65% | 11.13% |
| Safety | ||||
| Net Debt / EBITDA | 1.78 | 3.46 | 23.52 | 1.75 |
| Interest Coverage | 0.00 | 0.00 | -56.16 | -255.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |